Filters
Catalog peptides
Synthesis of unnatural amino acids and other blocks

Pasireotide

Name
Pasireotide
Molecular structural formula
CAS Number
396091-73-9
Formula
C58H66N10O9
MW
1047.23
Sequence Shortening
Cyclo[{4-(NH2-C2H4-NH-CO-O-)Pro}-Phg-{D-Trp}-K-{Tyr(4-Bzl)}-F]
Sequence
Cyclo[{4-(NH2-C2H4-NH-CO-O-)Pro}-Phg-{D-Trp}-Lys-{Tyr(4-Bzl)}-Phe]
InChIKey
VMZMNAABQBOLAK-DBILLSOUSA-N
Purity
≥98%
References
[1]. Lewis I, et, al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem. 2003 Jun 5;46(12):2334-44. [2]. Quinn TJ, et, al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery. 2012 Dec;152(6):1068-77. [3]. Schmid HA, et, al. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008 May 14;286(1-2):69-74. [4]. Imhof AK, et, al. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis. Arthritis Rheum. 2011 Aug;63(8):2352-62.
Target
Somatostatin Receptor
* All products on our website are for scientific research and cannot be used in human body
Product details
Data download

Pasireotide is a long-acting cyclic hexapeptide somatostatin analog that effectively reduces the secretion of GH (growth hormone), IGF-I (insulin-like growth factor-I) and ACTH (adrenocorticotropic hormone) by inhibiting the action of somatostatin receptors.